Leiden Jeffrey M's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 16, 2024
- Accession no.
- 0000875320-24-000064
- Filed
- Feb 16, 2024
- Trade date
- Feb 14-15, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $3.78M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leiden Jeffrey MCIK 0001242825 | Director, Officer (Executive Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $419.04 (range $419.00 to $419.38).
Referenced by the price of 1 transaction in Table I.